Background: MicroRNAs miR-9-3 and miR-193a have recently been found to be hypermethylated in a variety of non-small cell lung cancer (NSCLC) cells and primary human tumors. The objectives of this study were to investigate the role of demethylation of miR-9-3 and miR-193a genes in regulating proliferation and apoptosis in NSCLCs, and to decipher the potential mechanisms underlying the properties. Methods: MTT and population doubling time by flow cytometry were used to assess cell proliferation. Enzyme-Linked Immunosorbent Assay and caspase-3 activity assay were employed to evaluate apoptosis. Real-time RT-PCR and Western blot were used to quantify gene expression at mRNA and protein levels, respectively. Methylation-specific PCR was utilized to assess methylation status. Results: We found that demethylation agent 5-Aza-
resulting in gene reexpression. Moreover, a synergistic effect of 5-AzaC and the histone deacetylase inhibitor trichostatin A (TSA) in gene reexpression of epigenetically silenced genes has been documented [26] . Use of these agents robustly increased expression of miR-9-3 and miR-193a in NSCLC, presumably by demethylation. These demethylating agents provide a unique and efficient pharmacological probe for studying the role of miRNA demethylation in NSCLC.
These findings prompted us to propose that demethylation of miR-9-3 and miR193a genes may produce proliferation-inhibiting and apoptosis-promoting effects due to repression of NF-κB and MCL1 by miR-9-3 and miR-193a. This study was conducted to test our hypothesis in seven NSCLC cell lines with varying methylation statuses of both miR-9-3 and miR-193a.
Materials and Methods

Cell culture
The NSCLC cell lines A427, NCI-H1975, and NCI-H1993 were purchased from the American Type Culture Collection (Manassas, VA) and were grown in 5% CO 2 at 37°C in RPMI 1640 medium with high glucose (4.5 g/L; GIBCO-BRL, MD), supplemented with 10% fetal bovine serum (Hyclone, Logan, Utah). The cell lines were chosen according to their methylation status of miR-9-3 and miR-193a: NCI-H1993 and NCI-H1915 (miR- ), based on the study reported by Heller et al. [9] .
Drug treatment
To achieve DNA demythylation, a total of 2×10 5 NSCLC cells/mL were treated with 0.5 μmol/L 5-Aza-2′-deoxycytidine (5-AzaC, Sigma, St. Louis, MO) for 3 days, during which medium was replaced daily. Control cells were not drug treated.
To induce apoptotic cell death, NSCLC cells in culture were incubated with doxorubicin (0.5 µmol/L) for 48 h [27] .
MTT assay for cell proliferation
The WST-1 kit (Roche, Penzberg, Germany) was used to assess cell survival according to the manufacturer's instructions. In brief, 24 h after treatment with varying drugs or constructs, NSCLC cells were washed with PBS and then grown in 100 µl of fresh culture medium addition of 10 µl of WST-1 reagent for 30 min. The absorbance was measured at 425 nm using a Spectra Rainbow microplate reader (Tecan, Grödig, Austria) with a reference wavelength of 690 nm.
Determination of population doubling time (PDT)
Cell proliferation was determined by characterizing the log phase growth with population doubling time (PDT) which was calculated by using the equation: 1/(3.32 × (logN H -logN I )/(t 2 -t 1 ), where N H is the number of cells harvested at the end of the growth period (t 2 , 72 h) and N I is the number of cells at 5 h (t 1 ) after seeding [28] . Cells were counted by a flow cytometer (EPICS XL; Beckman, Inc.).
Enzyme-Linked Immunosorbent Assay (ELISA)
The Cell Death Detection ELISA kit (Roche Molecular Biochemicals) was employed to quantify DNA fragmentation of apoptotic cells on the basis of antibody detection of free histone and fragmented DNA, as detailed elsewhere [27, 29] . Optical density value was read by a microplate reader (GloMax®-96 Microplate Luminometer, Promega). Cellular Physiology and Biochemistry caspase-3 activity was determined by comparing the OD reading from the induced apoptotic sample with the level of the un-induced control.
Quantitative real-time RT-PCR analysis
The total RNA samples were isolated with Ambion's mirVana miRNA Isolation Kit, from NSCLC cells. The mirVana™ qRT-PCR miRNA Detection Kit (Ambion) was employed with real-time PCR with TaqMan for quantification of miRNAs. RT Reactions contained mirVana qRT-PCR primer sets specific for human miR-9-3 and miR-193a, and a scrambled miRNA as a negative control. qRT-PCR was performed on a thermocycler ABI Prism® 7500 fast (Applied Biosystems) for 40 cycles. Fold variations in expression of an mRNA between RNA samples were calculated. The threshold cycle (C T ) is defined as the fractional cycle number at which the fluorescence passes the fixed threshold.
Western blot analysis
The protein samples (cytosolic) were extracted from cultured NSCLC cells for immunoblotting analysis. Protein samples were quantified by BCA Protein Assay Kit with bovine serum albumin as the standard. Each protein sample at an amount of 50 µg was fractionated by SDS-PAGE (12% polyacrylamide gels) and then transferred to PVDF membrane (Millipore, Bedford, MA). The sample was then incubated overnight at 4°C with the primary antibodies in 1:1200: affinity purified goat polyclonal anti-NF-κB (p65) (Santa Cruz Biotechnology Inc.) and goat polyclonal anti-MCL1 (Santa Cruz Biotechnology Inc.). Next day, the membrane was incubated with secondary antibodies (Molecular Probes) diluted in PBS for 2 h at room temperature. Finally, the membrane was rinsed with PBS before scanning using the Infrared Imaging System (LI-COR Biosciences). GAPDH was used as an internal control for equal input of protein samples, using anti-GAPDH antibody (Santa Cruz Biotechnology Inc.). Immunoblot band density was quantified using QuantityOne software by measuring the band intensity (Area × OD) and normalizing to GAPDH. Relevant data are expressed as fold changes by normalizing the data to the control values.
Synthesis of miRNAs and anti-miRNA antisense inhibitors miR-9-3 (5'-UCU UUG GUU AUC UAG CUG UAU GA-3'), miR-193a (5'-AAC UGG CCU ACA AAG UCC CAG U-3'), their respective antisense oligonucleotides AMO-9-3 (5'-TCA TAC AGC TAG ATA ACC AAA GA-3') and AMO-193a (5'-ACT GGG ACT TTG TAG GCC AGT T-3'), the complex antisense inhibitors targeting both miR-9-3 and miR-193a (cAMO: 5'-ACT GGG ACT TTG TAG GCC AGT T tttttTCATACAGCTAGATAACCAAAGA-3'), and mismatched cAMO (MM-cAMO: 5'-TtAgaTtaCCCGCgcAGACCCTtttttTagTcCgaCTAGcgAACCAAAGA-3'; the underlined low-case letters indicate nucleotide replacement) [30] were synthesized by Integrated DNA Technologies Inc (IDT). Five nucleotides or deoxynucleotides at both ends of the antisense molecules were modified with the ribose ring being constrained by a methylene bridge between the 2'-O-and the 4'-C atoms to enhance cellular stability and target affinity [31] .
Transfection procedures
NSCLCs were transfected with miRNA (10 nmol/L), cAMO (2 nmol/L), AMO-9-3 (2 nmol/L) or AMO-193a (2 nmol/L), or negative control AMOs, with lipofectamine 2000 (Invitrogen), according to manufacturer's instructions. Forty-eight hours after transfection, cells were used for measuring proliferation and apoptosis, or were collected for total miRNA or protein purification.
DNA methylation analysis
DNA methylation for miR-9-3 and miR-193a was analyzed by bisulfate conversion of DNA (500 ng/ reaction) using the EZ DNA Methylation-Gold™ Kit (Zymo). Methylation-specific PCR (MS-PCR) of miR-9-3 and miR-193a was performed using the GoTaq™.
DNA Polymerase (Promega) with 30 cycles reactions [32, 33] . The primer pairs used for MS-PCR were based on the study reported by Heller et al [9] . For miR-9-3, forward: 5'-GTG YGT GTG TTT GTT TAT TTT-3' and reverse: 5'-ACC TCC CTT AAC CAA TAC C-3'; for miR-193a: forward: 5'-TTT GAG GGA TAT TTA GAG TTT YGG-3' and reverse: 5'-CAA CTC CCA TCC TCR AAA TT-3'. The expected PCR products are 141 kb for miR-9-3 and 115 kb for miR-193a. Each reaction was composed of known positive and negative water controls. PCR products were run on a 2.0% agarose gel and were visualized with UV transillumination (Kodak).
Data analysis
All data are expressed as mean±SEM. Statistical comparisons among multiple groups were performed by analysis of variance (ANOVA). If significant effects were indicated by ANOVA, a t-test with Bonferroni correction was used to evaluate the significance of differences between individual means. Otherwise, baseline and drug data were compared by paired Student′s t-test and age-matched comparisons between control and treatment were done by unpaired Student's t-test. A two-tailed p<0.05 was taken to indicate a statistically significant difference. All statistical tests were performed using SPSS 19.0.
Results
Verification of methylation status of seven NSCLC cell lines before and after 5-AzaC
Seven NSCLC cell lines were chosen for our study based on their differential miR-9-3 and mkiR-193a methylation statuses as reported by Heller et al [9] . We first conducted methylation-specific PCR (MS-PCR) analysis to verify the methylation statuses of the seven cell lines under our experimental conditions. As depicted in Figure 1 
Inhibition of proliferation and promotion of apoptosis by demethylation agent 5-AzaC
All NSCLC cell lines tested, except for H1703 (miR-9-3 − /miR-193a − ), exposed to 5-AzaC (0.5 μmol/L) demonstrated significantly reduced cell number and lengthened PDT, as determined by MTT assay and flow cytometry method, respectively, compared with mocked-treated cells ( Fig. 2A & 2B) . Intriguingly, the degrees of decrease in cell number and prolongation of PDT were both in the order of NCI-H1993/NCI-H1915 > A427/NCI-H2073 > NCI-H1975/NCI-H200 > H1703.
After treatment with doxorubicin (Dox; 0.5 µmol/L), apoptotic cell death of NSCLCs was observed, as reflected by the increased optical density (OD) values as an indicator of DNA defragmentation measured by ELISA (Fig. 3C) . The percentage of apoptosis was in the order of H1703 > NCI-H1975/NCI-H200 > A427/NCI-H2073 > NCI-H1993/NCI-H1915. The Dox-induced apoptosis in all three NSCLCs was considerably exacerbated in the presence of 5-AzaC. Strikingly, the order of apoptotic cell death according to the severity was converted to NCI-H1993/NCI-H1915 > A427/NCI-H2073 > NCI-H1975/NCI-H200 > H1703 (Fig. 2C) . 
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Upregulation of miR-9-3 and miR-193a by demethylation agent 5-AzaC
As the first step to exploit the potential role of altered methylation status of miR-9-3 and miR-193a in mediating the proliferation-inhibiting and apoptosis-promoting effects of demethylation agent 5-AzaC, we quantified the levels of miR-9-3 and miR-193a in all three NSCLC cell lines. Consistent with previously published studies [7] , we observed that 5-AzaC robustly upregulated the levels of miR-9-3 and miR-193a in NSCLCs. Notably, the four different groups of NSCLC cell lines showed four distinct patterns of upregulation: miR-9-3 and miR193a were concomitantly and equally increased in NCI-H1993/NCI-H1915; the increase in miR-193a level was substantially greater than in miR-9-3 in A427/NCI-H2073; miR-9-3 was elevated to a greater extent than miR-193a in NCI-H1975/NCI-H200; and neither miR-9-3 nor miR-193a was altered in H1703 (Fig. 3) . These data are in line with the study reported by Heller et al [9] unraveling the methylation status of NCI-H1993/NCI-H1915 (miR-9-3 3 . Upregulation of miR-9-3 and miR-193a by 5-AzaC in seven NSCLC cell lines. Note that the different NSCLC cell lines had distinct patterns of upregulation of miR-9-2 and miR-193a: both miRNAs were significantly upregulated in NCI-H1993/ H1915; only miR-193a was significantly upregulated in A427/H2073; only miR-193a was significantly upregulated in NCI-H1975/H200, and neither miR-9-3 nor miR-193a was altered in NCI-H1703. **p<0.01 vs Ctl; ***p<0.001 vs Ctl; n=5 batches of cells/group. 
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Attenuation of the effects of 5-AzaC by knocking down miR-9-3 and miR-193a
It was anticipated that if upregulation of miR-9-3 and miR-193 is truly involved in proliferation-inhibiting and apoptosis-promoting effects of 5-AzaC, knockdown of these miRNAs in the presence of 5-AzaC should significantly abrogate, if not completely eradicate, the effects of 5-AzaC. Our experiments indeed verified this notion. As illustrated in Fig. 4A , in cells transfected with the complex antisense inhibitors targeting both miR-9-3 and miR193a (cAMO; 2 nM) substantially mitigated the proliferation-inhibiting effects of 5-AzaC in all three NSCLCs, as indicated by the reversal of PDT lengthening by cAMO in the presence of 5-AzaC. Consistently, the 5-AzaC-evoked enhancement of Dox-induced apoptosis was also pronouncedly attenuated by cAMO (Fig. 4B) . It was noted that both the proliferationenhancing and apoptosis-suppressing effects of cAMO were found much greater in NCI-H1993/NCI-H1915 than in other NSCLC cell lines. In all cases, the mismatch cAMO (MMcAMO) failed to alter the proliferation-inhibiting and apoptosis-promoting effects of 5-AzaC.
The efficacy of cAMO in knocking down miR-9-3 and miR-193a was verified, with MMcAMO as a negative control (Fig. 4C, D) .
Inhibition of proliferation and promotion of apoptosis by miR-9-3 and miR-193a overexpression
To acquire additional evidence for the role of miR-9-3 and miR-193a upregulation through demethylation by 5-AzaC in suppressing proliferation and promoting apoptosis of NSCLCs, we examined if forced expression of these two miRNAs is sufficient to elicit the effects in the absence of 5-AzaC. As displayed in Fig. 5 , transfection of either of the two miRNAs produced considerable prolongation of PDT and increases in Dox-induced apoptosis in all three cell lines. For a given miRNA, the strength of effects was nearly the same in all three NSCLCs; but between the two miRNAs, the effects of miR-9-3 overexpression appeared to be moderately but significantly greater than miR-193a.
Downregulation of NF-κB and Mcl-1 by demethylation agent 5-AzaC
If demethylation of miR-9-3 and miR-193a genes indeed contributed to the observed effects of 5-AzaC, then the expression their putative target genes should be downregulated. 
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To test this notion, we went on to analyze the expression of their target genes at the protein level under various conditions. According to computational prediction, NF-κB and Mcl-1 are the candidate target genes for mR-9-3 and miR-193a, respectively (Fig. 6) , and NF-κB has been established as a target gene for miR-9 [34, 35] and Mcl-1 as a target gene for miR193a [36, 37] . Reciprocal relationships in terms of their expression levels between miR-9-3 and NF-κB, and between miR-193a and Mcl-1 were consistently observed. Specifically, after exposure to 5-AzaC, miR-9-3 and miR-193a were upregulated (Fig. 3) whilst NF-κB and Mcl-1 were downregulated, and these changes were eliminated by cAMO (Fig. 7A) . However, distinct patterns of the relationships were observed among the four different groups of NSCLCs. First, both of the inverse relationships between miR-9-3 and NF-κB and between miR-193a and Mcl-1 were seen in NCI-H1993/NCI-H1915. Secondly, NCI-H1975/ NCI-H200 demonstrated only an inverse relationship between miR-9-3 and NF-κB, and A427/NCI-H2073 cells only showed an inverse relationship between miR-193a and Mcl-1. Furthermore, the reciprocal relationship between miR-9-3 and NF-κB was eliminated only by AMO-9-3 (antisense specific for miR-9-3); likewise, the reciprocal relationship between miR-193a and Mcl-1 was eliminated only by AMO-193a (antisense specific for miR-193a) but not by AMO-9-3 (Fig. 7B) . Additionally, forced expression of mR-9-3 and miR-193a downregulated NF-κB and Mcl-1 protein levels, respectively (Fig. 7C) .
Discussion
The objective of this study was to investigate the roles of demethylation of miR-9-3 and miR-193a genes in regulating proliferation and apoptosis in NSCLCs, and to decipher the potential target mechanisms underlying the properties. The main findings of this study include: (1) Demethylation agent 5-AzaC concomitantly upregulated expression of miR-9-3 and miR-193a and downregulated their respective target genes NF-κB and Mcl-1, accompanied by inhibition of proliferation and promotion of doxorubicin-induced apoptosis in three NSCLCs tested; (2) The effects of 5-AzaC were abolished by concomitant knockdown of miR-9-3 and miR-193a using the complex antisense technique, whereas forced ectopic expression of miR-9-3 and miR-193a mimicked the effects of 5-AzaC; And (3) the degrees of proliferation inhibition and apoptosis promotion elicited by 5-AzaC were both in the order of NCI-H1993 > A427 > NCI-H1975. Collectively, we conclude that methylation of miR-9-3 and miR-193a genes to silence their expression so as to upregulate the anti-apoptotic NF-κB and Mcl-1 may be an epigenetic mechanism for carcinogenesis, and demethylation to re-activate tumor suppressor miRNAs miR-9-3 and miR-193a contributes, at least partially, to the anti- One study documented that ectopic expression of miR-9 strongly accelerates terminal myelopoiesis and promotes apoptosis in vitro and in vivo via targeting FoxO1 and FoxO3 [32] . In another study, ectopic expression of miR-9 was found to inhibit cell proliferation, migration and invasion in gastric cancer cells [33] . Still another study showed that miR-9 regulates E-cadherin and cancer metastasis [30] . We unraveled here that miR-9-3 overexpression of miR-9-3 either by demethylation or by forced expression suppressed proliferation and enhanced apoptosis in NSClCs. In addition to NSCLCs showed in this study and some previous studies [9−15] , methylation of miR-9-3 has also been described in a number of cancer cells of other tissue origins, including gastric cancer cells [33, 38] , hepatocellular carcinoma [39] , bladder cancer [40] , oropharyngeal squamous cell carcinomas [41] , and renal cell carcinoma [42] . Based on our findings in this study, it is not unreasonable to speculate that demethylation of miR-9-3 may also produce anti-cancer effects in other types of cancers. Similarly, miR-193a has also been identified as a methylation-silenced tumor suppressor in a variety of cancers [16] [17] [18] 43] . Moreover, downregulated miR-193a expression was reported in LSCC, malignant melanomas, oral squamous cell carcinomas (OSCC), and acute myelogenous leukemia [16, 18, 44, 45] . Together with our findings in this study, it is quite plausible that methylation is also an important mechanism to inactivate miR-193a expression for cancer generation and progression.
We found that doxorubicin evoked only a smaller degree of apoptosis under normal culture conditions, and its proapoptotic property was manifested after cells had been exposed to 5-AzaC for DNA demethylation. Moreover, the apoptosis-promoting effect of 5-AzaC was effectively mitigated by knocking down miR-9-3 and miR-193a. These results suggest that methylation of miR-9-2 and miR-193a contributes to conferring the drug resistance to NSCLCs and demethylation of these miRNAs is able to restore the drug sensitivity of NSCLCs.
The fact that there were consistently distinct patterns in the three different NSCLCs in response to 5-AzaC treatment in terms of proliferation inhibition, apoptosis promotion, upregulation of miR-9-3 and miR-193a, and downregulation of NF-κB and Mcl-1 protein levels may be best explained by differences in the methylation status of the NSCLCs. NCI-H1993/ NCI-H1915 cells responded with highest sensitivity to 5-AzaC, suggesting that both miR-9-3 and miR-193a are highly methylated in this cell line. By comparisons, NCI-H1975/NCI-H200 and A427/NCI-H2073 appeared to have higher degrees of methylation in miR-9-3 and miR193a, respectively. These results are in agreement with the findings by Heller et al [9] who revealed the methylation status as NCI-H1993/H1915 (miR-9-3 Taken together, our study provides strong evidence that methylation-silencing of miR-9-3 and miR-193a, as of other miRNAs and protein-coding genes [46−48] , is an important epigenetic mechanisms favoring cancer cell growth and survival in NSCLCs and likely in other cancers as well, and demethylation to reactivate expression of miR-9-3 and miR-193a genes may be a novel epigenetic therapeutic strategy for the treatment of human NSCLCs. However, it should be emphasized that our study merely provides a piece of evidence for the role of methylation status of the two miRNAs in regulating apoptosis of NSCLCs, and we should not generalize this conclusion solely based on the results from seven cell lines. To confirm this issue with sufficient data, rigorous experimental studies in more cells or in other models are definitely required in the future.
